Kishibayashi N, Karasawa A
Department of Pharmacology, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Jpn J Pharmacol. 1995 Nov;69(3):269-72. doi: 10.1254/jjp.69.269.
We examined the effects of KW-5092 ((1-[2-[[[5-(piperidinomethyl)-2-furanyl]methyl]-amino]ethyl]- 2-imidazolidinylidene) propanedinitrile fumarate), a novel gastroprokinetic agent, on gastric mucosal blood flow (GMBF) in anesthetized rats. Intravenous infusion of KW-5092 (0.1 mg/kg/min for 30 min), which did not affect the basal GMBF, reversed the norepinephrine (1 microgram/kg/min, i.v. infusion for 30 min)-induced decline of GMBF in the corpus and the antrum. The improvement by KW-5092 of the GMBF was abolished by atropine (0.1 mg/kg/min, i.v. infusion for 30 min). These results suggest that KW-5092, via cholinergic activation, could counteract the decline of GMBF induced by adrenergic activation.
我们研究了新型促胃动力药KW - 5092（富马酸（1 - [2 - [[[5 - （哌啶甲基） - 2 - 呋喃基]甲基] - 氨基]乙基] - 2 - 咪唑烷叉）丙二腈）对麻醉大鼠胃黏膜血流量（GMBF）的影响。静脉输注KW - 5092（0.1毫克/千克/分钟，持续30分钟），这并未影响基础GMBF，却逆转了去甲肾上腺素（1微克/千克/分钟，静脉输注30分钟）诱导的胃体和胃窦GMBF下降。KW - 5092对GMBF的改善作用被阿托品（0.1毫克/千克/分钟，静脉输注30分钟）消除。这些结果表明，KW - 5092可通过胆碱能激活来抵消肾上腺素能激活诱导的GMBF下降。
